Nova Biomedical Diagnoses Success after Testing the Limits of Their New Multicurrency Budgeting and Consolidation Process
Nova Biomedical Diagnoses Success after Testing the Limits of Their New Multicurrency Budgeting and Consolidation Process
2 Pages1.800.366.5111 • www.centage.com Nova Biomedical Diagnoses Success after Testing the Limits of Their New Multicurrency Budgeting and Consolidation Process ABOUT Now in its 40 th year , Nova Biomedical is a world leader in developing and manufacturing advanced blood analyzers and diagnostic meters. Known primarily for its diabetic blood-testing devices, Nova has distributors in 91 countries and operates several wholly owned subsidiaries, including operations in Brazil, Canada, France, Germany, the U.K., Japan, Taiwan and Italy. CHALLENGE Nova Biomedical’s global presence presented a number of logistical, operational and financial challenges. Preparing full multicurrency consolidations of their financial statements in a massive Excel spreadsheet became too onerous to manage despite
